TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35714315
Drug: Augmented therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented therapy in high-risk group
Study: 35714315
Drug: Augmented therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented therapy in cytogenetic high-risk patients
Study: 35714315
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy in cytogenetic high-risk patients
Study: 32545655
Drug: CC +
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC + HF group
Study: 32545655
Drug: CC +
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC + MF group
Study: 33341707
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose nab-paclitaxel (LD180) 180 mg/m2
Study: 36072931
Drug: Sitagliptin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin plus Metformin (100mg sitagliptin and 500mg metformin three times per day)
Study: 34118179
Drug: Pirepemat 350
Normalized name: Pirepemat
DrugBank: Pirepemat (DB19165)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirepemat 350 mg single dose
Study: 34118179
Drug: Pirepemat 100
Normalized name: Pirepemat
DrugBank: Pirepemat (DB19165)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirepemat 100 mg multiple doses (3 times daily for 7 days)
Study: 34118179
Drug: Pirepemat 250
Normalized name: Pirepemat
DrugBank: Pirepemat (DB19165)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirepemat 250 mg multiple doses (3 times daily for 7 days)
Study: 34118179
Drug: Pirepemat (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirepemat (all doses)
Study: 35348246
Drug: Prediction model
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction model for postoperative severe ALI based on variables including coronary heart disease, cardiopulmonary bypass (CPB) ≥ 257.5 min, left atrium diameter ≥ 35.5 mm, hemoglobin ≤ 139.5 g/L, preCPB OI ≤ 100 mmHg, intensive care unit OI ≤ 100 mmHg, left ventricular posterior wall thickness ≥ 10.5 mm, neutrophilic granulocyte percentage ≥ 0.824.
Study: 33852204
Drug: Initial triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial triple therapy with metformin, pioglitazone, and exenatide
Study: 33852204
Drug: Stepwise conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepwise conventional therapy with metformin followed by glipizide and then glargine insulin
Study: 34675150
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Group C)
Study: 35839791
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (1.5 g cefuroxime, intramuscular in Norway or intravenous in Germany)
Study: 32638035
Drug: Escitalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (20 mg)
Study: 35880252
Drug: Closed-loop insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop insulin delivery with fast-acting insulin aspart
Study: 35880252
Drug: Standard insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard insulin therapy (control group)
Study: 34726850
Drug: Astra Tech
Normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Astra Tech implants (group A)
Study: 34726850
Drug: Brånemark implants
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brånemark implants (group B)
Study: 33419900
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy
Study: 36008143
Drug: Prednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (1 mg/kg for 10 days)
Study: 32546554
Drug: Cabozantinib 60
Normalized name: cabozantinib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 60 mg daily as maintenance therapy
Study: 33921829
Drug: Placebo supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplement
Study: 34010934
Drug: Topical estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical estrogen therapy (n=12)
Study: 35543701
Drug: Creatine kinase
Normalized name: Creatine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine kinase levels during statin treatment
Study: 32419559
Drug: Other biotin-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other biotin-containing supplements recommended by physicians
Study: 33439250
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (open reduction and internal fixation using a volar-locking plate)
Study: 33909355
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus medication
Study: 35357606
Drug: CultActive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CultActive treatment (A23187 ionophore), 122 MII oocytes treated
Study: 35357606
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment), 125 MII oocytes
Study: 35357606
Drug: CultActive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CultActive treatment (A23187 ionophore)
Study: 34168003
Drug: Intracerebral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracerebral administration of ipilimumab (IPI) 10 mg (cohort-1)
Study: 34168003
Drug: Intracerebral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracerebral administration of ipilimumab (IPI) 5 mg plus nivolumab (NIVO) 10 mg (cohort-2)
Study: 34168003
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of nivolumab (NIVO) 10 mg, repeated every 2 weeks (max. five administrations)
Study: 33099227
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (1.4 mg every other day)
Study: 34486272
Drug: Standard antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibacterial therapy
Study: 34166834
Drug: GDC-3280 (25–1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC-3280 (25–1600 mg single dose)
Study: 34166834
Drug: GDC-3280 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC-3280 (200 mg or 275 mg twice daily for 7 days)
Study: 34166834
Drug: GDC-3280 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC-3280 (400 mg and 800 mg single dose with food)
Study: 34166834
Drug: GDC-3280 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC-3280 (400 mg and 800 mg single dose)
Study: 34166834
Drug: GDC-3280 (repeat
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC-3280 (repeat doses)
Study: 34166834
Drug: GDC-3280 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC-3280 (single doses)
Study: 35654691
Drug: ACT/control (cetuximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT/control (cetuximab + irinotecan‐based chemotherapy)
Study: 32384122
Drug: Encala™ treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encala™ treatment
Study: 36262803
Drug: Neoadjuvant hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant hormone therapy (NHT) with anastrozole for at least six months (menopausal patients) or anastrozole with subcutaneous goserelin acetate every 12 weeks for at least six months (premenopausal women).
Study: 36262803
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NCT) with a standard institutional regimen based on anthracyclines and taxanes.
Study: 34119409
Drug: Intervention bundle
Normalized name: oxymetazoline
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention bundle (vitamin C sprays, peppermint water mouthwash, lip moisturiser)
Study: 34119409
Drug: Placebo interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo interventions (saline sprays, 40 °C water mouthwash, wetting lips with water)
Study: 33368499
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg/day
Study: 35732396
Drug: Treatment Group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Group 1 - smart electronic toothbrush, educational booklet
Study: 35551845
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of cannabidiol
Study: 32151503
Drug: Modified constraint-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified constraint-induced movement therapy (mCIMT), 1 hour therapy sessions for 14 consecutive days, normal arm constrained for 6 hours per day.
Study: 32038017
Drug: Oral solutions
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solutions enriched with maltodextrin
Study: 32993815
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo and omeprazole 20 mg single dose 6 h before RAI therapy followed by oral placebo and omeprazole 20 mg daily for 3 days.
Study: 32417348
Drug: Dose‐escalated IMRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose‐escalated IMRT
Study: 35397249
Drug: SWITCH group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: SWITCH group (monotherapy with either FGA or SGA)
Study: 35397249
Drug: STAY group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: STAY group (combination treatment of FGA and SGA)
Study: 32696522
Drug: Luspatercept (0.2-1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luspatercept (0.2-1.25 mg/kg, subcutaneously once every 3 weeks)
Study: 33166594
Drug: 38 %
Normalized name: dextrose 38 % in water
Approvals — FDA: no, EMA: no, PMDA: no
Description: 38 % silver diamine fluoride (SDF) solution followed by placebo varnish
Study: 35988083
Drug: Olfactory training
Normalized name: BOS TAURUS OLFACTORY BULB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olfactory training (daily sessions for 3 months)
Study: 35500264
Drug: Daily liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily liraglutide
Study: 33637061
Drug: MOVE group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOVE group treatment (MOVE-G)
Study: 33637061
Drug: MOVE individual
Normalized name: chondroitin sulfates
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOVE individual treatment (MOVE-I)
Study: 33637061
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (MOVE-G and MOVE-I)
Study: 34049452
Drug: Oral cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cannabis (10 mg THC)
Study: 34049452
Drug: Blood THC
Normalized name: BLOOD TEST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood THC concentrations after inhalation
Study: 33982406
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% cyclopentolate hydrochloride
Study: 33982406
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% cyclopentolate hydrochloride combined with 2.5% phenylephrine
Study: 33776997
Drug: Galantamine 8
Normalized name: galantamine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine 8 mg daily for 4 weeks
Study: 32277344
Drug: Two-step infusion
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two-step infusion of imipenem (1.0 g q8h)
Study: 33413049
Drug: AMCAFF (caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMCAFF (caffeine 3 mg/kg in the morning)
Study: 32900336
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of therapy until target pH is achieved
Study: 34267156
Drug: 7.5% hypertonic
Normalized name: SODIUM CHLORIDE 7.5 g in 100 mL ORAL LIQUID [7.5% Hypertonic Saline]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% hypertonic saline (HTS) (2 mL/kg)
Study: 34267156
Drug: 20% mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% mannitol (4.6 mL/kg)
Study: 38902928
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg hydrocortisone
Study: 38902928
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg yohimbine
Study: 33860721
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg hydrocortisone/10 mg yohimbine combined
Study: 34719711
Drug: Palliative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative care screening tool administered daily for 8 weeks
Study: 33811649
Drug: Group counseling
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group counseling based on the solution-focused approach (SFA)
Study: 32741505
Drug: Integrated Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Cognitive Behavioral Treatment (I-CBT)
Study: 33475138
Drug: Sitagliptin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin + insulin (SITA)
Study: 32428718
Drug: Sleep-promoting intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep-promoting intervention with eye patches and earplugs
Study: 34244327
Drug: Estimated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estimated treatment cost per injury
Study: 35607304
Drug: Dexmedetomidine (added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (added to control group treatment)
Study: 34014975
Drug: Self-medication for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-medication for headache
Study: 32366238
Drug: Reasons for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reasons for self-medication
Study: 35565715
Drug: Hyperhomocysteinemia defined
Normalized name: refined almond oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperhomocysteinemia defined as levels ≥ 15 µmol/L
Study: 35565715
Drug: Boys (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boys (mean homocysteine levels 14.1 µmol/L)
Study: 34691079
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) initiation
Study: 35235092
Drug: CBD (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD (300 mg; oral)
Study: 32299734
Drug: Fentanyl and
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl and midazolam (0.1 mg fentanyl and 5 mg midazolam)
Study: 32299734
Drug: Pethidine and
Normalized name: pethidine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine and diazepam (25 mg pethidine and 5 mg diazepam)
Study: 32407272
Drug: Metoclopramide 20
Normalized name: metoclopramide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 20 mg (Maxolon 10 mg, GlaxoSmithKline, Pakistan) administered after rifampicin treatment
Study: 32789625
Drug: Perceived efficacy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived efficacy of daily HIV pill
Study: 34551471
Drug: Control (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (2 ml saline IV)
Study: 34323977
Drug: M2-deficient single
Approvals — FDA: no, EMA: no, PMDA: no
Description: M2-deficient single replication (M2SR) vaccine
Study: 34527408
Drug: 1 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg/kg fentanyl (group 2)
Study: 34527408
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dexamethasone (group 1)
Study: 34527408
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dexamethasone + 1 μg/kg fentanyl (group 3)
Study: 33008345
Drug: Guanfacine extended-release
Normalized name: Guanfacine Extended-Release Tablets
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guanfacine extended-release (GXR), starting dose 2 mg/day, maintenance dose 4-6 mg/day for 50 weeks
Study: 38314010
Drug: Conventional Physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Physical Therapy (CPT)
Study: 38917366
Drug: Standard antidepressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antidepressants
Study: 34191185
Drug: Bilirubin (per
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilirubin (per 10 µmol/l increase)
Study: 32091953
Drug: Bilateral and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral and unilateral treatments
Study: 35074399
Drug: RXD2: xylazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RXD2: xylazine (0.2 mg/kg) and doxapram (0.2 mg/kg)
Study: 33330899
Drug: Decaffeinated green
Normalized name: (-)-EPIGALLOCATECHIN-3-O-GALLATE (EGCG) (CONSTITUENT OF POWDERED DECAFFEINATED GREEN TEA EXTRACT) [DSC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated green coffee extract (DGCE) 302 mg
Study: 36247104
Drug: Levobupivacaine 0.25%
Normalized name: levobupivacaine 0.25% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.25% (2 ml) plus dexmedetomidine 1 μg/kg diluted in 1 ml saline 0.9% (0.5 ml in each tonsil)
Study: 36247104
Drug: Levobupivacaine 0.25%
Normalized name: levobupivacaine 0.25% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.25% (2 ml + 0.5 ml saline 0.9% per tonsil)
Study: 35573842
Drug: Background infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Background infusion group (2 mL/h infusion, 10-min lockout time)
Study: 35573842
Drug: No background
Approvals — FDA: no, EMA: no, PMDA: no
Description: No background infusion group (6-min lockout time)
Study: 35573842
Drug: Background infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Background infusion group
Study: 33160719
Drug: Haloperidol (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (0.05 or 0.1 mg/kg)
Study: 35345661
Drug: Comprehensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive treatment group (Buqi Huoxue Decoction + cardiac rehabilitation care)
Study: 35345661
Drug: TCM +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCM + WM group (Buqi Huoxue Decoction + conventional treatment)
Study: 33975094
Drug: 5% lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine patch
Study: 36106759
Drug: Open-labeled placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-labeled placebo (OLP) administered as one tablet twice a day for 7 days, followed by 3 weeks of placebo for all patients.
Study: 38306389
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg)
Study: 35459970
Drug: Biological determinist
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological determinist condition
Study: 36477733
Drug: sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitagliptin 100 mg once daily
Study: 33331040
Drug: Novel dental
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel dental gel containing 2.6% EDTA
Study: 34181880
Drug: BNT162b2 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 (0.3 mL) via a single intramuscular injection
Study: 36185306
Drug: Weekly nurse
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly nurse monitoring phone call and educational leaflet
Study: 33428177
Drug: Sovateltide (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sovateltide (0.3 µg/kg, intravenous bolus over 1 min, three doses on day 1, day 3, and day 6)
Study: 39210472
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 3 months
Study: 36253717
Drug: Lidocaine +
Normalized name: Lidocaine + Menthol Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine + propofol (Group L)
Study: 35230203
Drug: ThePaS-I (Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ThePaS-I (Therapy Program for Adequate Sexual Behaviors Version 1) - offending-specific skills training
Study: 33287911
Drug: Human albumin
Normalized name: Human albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human albumin 20% (60-g loading dose over 2–3 h, followed by 40–80 g infusion to maintain serum levels at least 30 g/l for 28 days)
Study: 32362175
Drug: Personalized text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized text message support and a checklist for initiation of antihypertensive medication
Study: 32667223
Drug: Paediatric Autism
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paediatric Autism Communication Therapy
Study: 33651442
Drug: Oral TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TXA 250 mg bid
Study: 33651442
Drug: 100 mg/mL
Normalized name: urea 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/mL intradermal TXA
Study: 33651442
Drug: 4 mg/mL
Normalized name: valine 4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/mL intradermal TXA
Study: 34113408
Drug: Periarticular multimodal
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular multimodal cocktail injection without corticosteroids
Study: 33966891
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia (PCA) with morphine
Study: 39565030
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of antibiotic treatment
Study: 39565030
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days of antibiotic treatment
Study: 32994107
Drug: Sequential presentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential presentation of options (no test, 5-gene, then 15-gene)
Study: 33849683
Drug: Amphetamine 2.5
Normalized name: amphetamine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine 2.5 mg
Study: 33387550
Drug: Nitrous oxide/oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrous oxide/oxygen plus IANB using 2% lidocaine with 27 μg clonidine